ISSUE #18
Jan 7, 2026
📚
Browse Past Issues
Many exciting events and stories await in the year ahead.
We hope you’ll continue to join us and stay tuned👀
Looking forward to sharing another
great 2026 together!
🥳 Wishing you a happy New Year!
We’ve refreshed the Overview section on our website with a compact visualization of the
2025 Bioindustry Survey
, including:
Distribution of companies by region
Workforce status
Investment status
Supply and demand trends
The
full report
is also
available in English!
👀 Take a look!
Connecting Korean Biotech Innovators with Global Partners!
(Almost here!)
6th
Global IR @JPM 2026
January 13, 2026
Dive into your next global biotech partnership!
(Almost here!)
Korea Night @JPM 2026
January 14, 2026
Where Korean Biotech Meets Global Opportunity
EAST-WEST BIOPHARMA SUMMIT: SEOUL 2026
March 9-11, 2026
Hansung Ko vows to drive Korea bio growth through global expansion and policy support
On Jan. 1, KoreaBIO President Hansung-Ko said, "We will make 2026 the first year in which Korea's bio industry proves its competitiveness in the global market and concentrate all of the association's capabilities on policy and system improvements and support for global expansion."
Jan 1, 2025
· via [Chosun Biz]
Korea’s Biotech Revolution Meets a Regulatory Wall: Why 2026 Is the Golden Time for Reform
The nation’s annual technology exports now exceed KRW 20 trillion, placing Korean firms among the world’s top innovation suppliers.
Dec 27, 2025
· via [KoreaTechDesk]
South Korea’s SeaWith to Cut Cultivated Beef Costs by 30% with New Supply Deal
Most Koreans are open to trying cultivated meat, but its high price markup remains the chief barrier to adoption.
Dec 27, 2025
· via [Green Queen Media]
Korean microbiome developers halt drug programs and pivot to cosmetics and supplements
Korean microbiome firms shift resources to cosmetics and supplements as drug trial successes remain scarce
Jan 4, 2026
· via [Chosun Biz]
AI-Designed B Cell–Reactive Neoantigens Open a New Chapter for Personalized Cancer Vaccines
Using machine learning trained on both structural and sequence features of mutant proteins, KAIST’s researchers managed to identify B cell–reactive neoantigens at scale.
Jan 5, 2026
· via [GeneOnline]
∎ K-bio sets sights on deals at
JPMorgan Healthcare Conference
- Pulse
∎ ABL Bio secures KRW 80.5 billion in
upfront payment
and
equity investment
from Eli Lilly for its ‘Grabody’ platform - THE BIO
∎ Celltrion
opens production site
in New Jersey - The Korea Times
∎ Daewoong Pharmaceutical
secures Indonesian marketing approval
for diabetes drug ‘Envlo’, marking full-scale entry into Southeast Asia - THE BIO
∎ ENCell and Japan's CRC
sign strategic partnership
for cell and gene therapy expansion - KBR
∎ Preclina
unveils world's first
HSc-based humanized pulmonary fibrosis model, positioning itself as a strategic partner for big pharma - THE BIO
∎ Samsung Bioepis
wins Japanese marketing approval
for autoimmune disease treatment ‘SB17’ - THE BIO
∎ ToolGen revalued after
U.S. EU patent wins
- Pharm EDaily
∎ Woojung Bio
partners with
Xellar to advance AI-enabled hybrid preclinical platforms - KBR
∎ Korea's First 'Standardized Dementia Cohort' Completed... Dementia Research Infrastructure
Reaches World-Class Level
- The Asia Business Daily
∎ Korea
sets up Philippines hub
to expand agricultural machinery exports in SEA - AgTechNavigator
∎ EASY BIO
Acquires U.S.
BioMatrix, Securing Both Polysaccharide Coating Technology and Pet Food Distribution Network -
The Asia Business Daily
∎
"First for a Korean Beauty Company"
... Kolmar Korea's AI Diagnostic and Treatment Device Wins CES 'Best Innovation Award' - The Asia Business Daily
∎ South Korea to Merge Two National Bio Committees into a
Single Body
- DongA Science
∎ ABL Bio and NovaBridge
Confirm Positive Data
for ABL111 in Phase 1b Dose Expansion Cohor - The Asia Business Daily
∎ Alteogen Signs Option Contract for Subcutaneous Injection
Technology Transfer
- Business Korea
∎ Korea’s
next homegrown drug
could be a first local CAR-T as payer keeps widening access - KBR
∎
MFDS Drug Approvals
Up 14.8% in 2025; Chong Kun Dang Leads with 40 Approvals - Newsmp
∎ Pharmaceuticals and Biotech
Lead Profitability
in Korea, U.S., Japan - THE CHOSUN Daily
∎ Korea opens door to B cell-based
personalised cancer vaccines
- BioSpectrum Asia
∎ KIST, Hanyang University Develop
Direct Fat-Removal Therapy
- THE CHOSUN Daily
∎ K-bio Milestone Payments
Jump 2.2-fold
in Two Years - Business Korea
∎ LG Chem alumni drive growth at SK and Samsung,
intensifying Korea bio talent war
- Chosun Biz
∎ South Korea
reforms regenerative medicine rules
to speed clinical research and treatment - Chosun Biz
∎ Why Are Korean Bio Companies Focusing on
"Radiopharmaceuticals"
? - The Asia Business Daily
∎ "From Infrastructure to Speed"... Korea
Gains Attention
as a Hub for Radiopharmaceutical Therapy Clinical Trials - The Asia Business Daily
∎ TissenBioFarm
Develops Cultivated Meat
Matching Cell Density of Real Meat - Vegconomist
📰
Join our press list
Get KoreaBIO updates
& media resources
💬
Share Your thoughts!
How was your letter today?
✉️
Korean Newsletter
Daily biotech news from Korea and around the world
— in Korean
Stay connected with
everything
KoreaBIO
Watch and Join!
Explore More
KoreaBIO (Korea Biotechnology Industry Organization)
700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
+82-31-628-0037
수신거부
Unsubscribe
